论文部分内容阅读
目的:探讨西非无并发症恶性疟疾的短程高效治疗策略。方法:选择2016年8-12月在塞拉利昂第34军医院和中塞两军热带传染病防控中心诊疗的无并发症恶性疟疾188例为研究对象,随机分为观察组A、B和对照组,观察组A患者口服复方蒿甲醚片3 d疗程,观察组B口服双氢青高蒿哌喹片2 d疗程,对照组口服双氢青高蒿哌喹片7 d疗程。比较各组临床疗效、再燃率和不良反应发生情况。结果:观察组A、B及对照组患者在第一用药疗程结束后,治愈率分别是93.6%、95.2%、95.1%,组间差异无统计学意义(P>0.05);随访8周再燃率观察组A为7.9%,高于观察组B和对照组,但两两比较差异无统计学意义。观察组A患者不良反应发生率最少,且与对照组比较差异有统计学意义(P<0.05);对照组患者肝功异常发生率相对较多,表现为丙氨酸转氨酶的轻度升高。结论:双氢青蒿素哌喹片和复方蒿甲醚片短程治疗西非无并发症恶性疟疾疗效显著,不良反应发生率低。
Objective: To explore the short-term high-efficiency treatment strategy of non-companied malignant malaria in West Africa. METHODS: A total of 188 cases of uncomplicated falciparum malaria diagnosed and treated by Tropical Diseases Control and Prevention Center, Sierra Leone Military Hospital and Central Serb Army from August to December in 2016 were selected as research objects and randomly divided into observation group A, B and control group , The observation group A patients oral administration of artemether tablets for 3 d course of treatment, the observation group B oral administration of dihydroperidol artesunate piperacillin tablets for 2 d course of treatment, the control group oral administration of dihydroergophthrene artemether tablets for 7 d course of treatment. Compare the clinical efficacy, reburning rate and adverse reactions. Results: The cure rates of group A, B and control group after the first course of treatment were 93.6%, 95.2% and 95.1%, respectively. There was no significant difference between the two groups (P> 0.05) Observation group A was 7.9%, higher than the observation group B and the control group, but no significant difference between the two groups. The incidence of adverse reactions in observation group A was the least, and the difference was statistically significant compared with the control group (P <0.05). In the control group, the incidence of abnormal liver function was relatively high, showing a mild increase of alanine aminotransferase. CONCLUSIONS: Dihydroartemisinin and piperacillin tablets combined with artemether short-course treatment of non-companied falciparum malaria in West Africa have significant efficacy and low incidence of adverse reactions.